Over 100 pharmaceutical companies are competing to develop 120+ pipeline drugs for non-small cell lung cancer (NSCLC), with approximately 30+ drugs in late-stage development. The competitive landscape is driven by precision oncology advances, including next-generation targeted agents and immunotherapy combinations. Recent FDA approvals and designations highlight innovation in treating EGFR-mutated, ALK-positive, and other biomarker-selected NSCLC populations.

Alethio Therapeutics announced ATX-011, a first-in-class mutation-agnostic antibody designed to treat Essential Thrombocythemia (ET), a $2B market. The candidate demonstrated rapid platelet normalization within days and a clean safety profile in non-human primate models, positioning it as a potential replacement for Hydroxyurea, the 50-year-old standard of care. The company appointed Steve R. Coats as Chief Development Officer to advance ATX-011 toward IND submission targeted for Q1 2027, with clinical proof-of-concept data expected in H1 2028.

The generalized myasthenia gravis (gMG) market is experiencing significant growth with 8 promising late-stage drug candidates in development. The gMG market across 7 major markets was valued at USD 5.9 billion in 2025 and is projected to grow at 9.1% CAGR through 2036. Key therapies in development include FcRn inhibitors, complement inhibitors, BTK inhibitors, and innovative CAR-T cell therapies from major pharmaceutical companies.

AIM ImmunoTech Inc. disclosed that its 2025 audited financial statements contain a going concern emphasis of matter from its independent auditors. Despite this, management expressed confidence in its ability to raise funds based on positive progress in Phase 2 clinical trials of its lead drug Ampligen combined with AstraZeneca's Imfinzi for treating metastatic pancreatic cancer. The company expects to release the next DURIPANC study update in June 2026.

The US eosinophilic esophagitis market is projected to grow at 13.2% CAGR through 2036, driven by increased disease awareness, standardized diagnostics, and high relapse rates. The market was valued at $647 million in 2025, with emerging therapies from major pharmaceutical companies expected to transform the treatment landscape, including TSLP inhibitors, glucocorticoid receptor agonists, and immunomodulators.

The castration-sensitive prostate cancer (CSPC) market is expected to grow significantly from $5.14 billion in 2025 to $11.75 billion by 2036, driven by an aging population, increased disease awareness, and successive drug approvals. Key therapies like XTANDI and ERLEADA are dominating the market, while newer treatments including PARP inhibitors and radioligand therapies are emerging. Recent approvals and expanded labels for existing drugs are accelerating market growth across major regions.

The SLE and LN market is projected to grow from $2.4 billion in 2024 to $5.9 billion by 2034 (9.6% CAGR), driven by 10 late-stage pipeline drugs offering improved safety and efficacy over current generic treatments. However, growth faces headwinds from biosimilar competition and high treatment costs limiting adoption rates.

The severe asthma drug development pipeline shows strong momentum with 30+ pharmaceutical companies actively developing 35+ pipeline therapies across various clinical stages. Key players including AstraZeneca, Generate Biomedicines, GSK, and others are advancing promising candidates targeting thymic stromal lymphopoietin inhibitors and interleukin pathways. Recent approvals and positive trial results, including GSK's Exdensur and Upstream Bio's verekitug, demonstrate progress in addressing this unmet medical need.

The idiopathic membranous nephropathy (IMN) market is expected to grow from USD 130 million in 2025 to USD 1 billion by 2036, driven by rising disease prevalence, improved diagnostics, and emerging targeted therapies. Multiple pharmaceutical companies are advancing novel treatments including SNP-ACTH (1-39) Gel, zanubrutinib, obinutuzumab, and povetacicept to address the substantial unmet need for more effective and better-tolerated therapies.

Q1 2026 saw the highest percentage of dividend increase announcements since 2019 at 45%, reflecting boardroom optimism despite macroeconomic uncertainty. However, a significant divide emerged: mega-cap companies (60%+ increase rate) aggressively hiked payouts, while small-cap firms remained cautious with only 38% increases. Regional divergence also appeared, with Asia-Pacific and Oceania experiencing broader dividend cuts.

The Trump administration is preparing to announce 100% tariffs on pharmaceutical companies that haven't secured pricing deals with the White House, potentially as soon as Thursday. The tariffs stem from a Section 232 investigation citing national security grounds. Major drugmakers including Pfizer, Eli Lilly, AstraZeneca, Novo Nordisk, and Johnson & Johnson have already secured three-year reprieves by agreeing to most-favored-nation pricing. The tariff threat is part of a broader pricing strategy that includes the TrumpRx.gov platform for comparing discounted drug prices.

Keymed Biosciences achieved a major windfall by spinning off its immunotherapy drug into a separate company (Ouro Medicines) that was subsequently acquired by Gilead Sciences for up to $2.175 billion. Keymed stands to receive approximately $320 million in total proceeds while retaining royalty rights. The transaction marks the first complete NewCo cycle exit by a Chinese drugmaker and demonstrates the effectiveness of this globalization strategy for Chinese biotech companies.